Podcasts about disease burden

Have you ever wondered what it takes for a startup, particularly in a niche field like women's health, to secure the necessary funding to move forward and make a meaningful impact? In this episode of The Angel Next Door Podcast, Marcia Dawood sits down with Mark Gannott, who brings a unique blend of neuroscience, economics, and entrepreneurship to the table. From navigating the complex landscape of women's health financing to shedding light on economic modeling and network strategies, Mark's insights are invaluable for anyone looking to understand the intricacies of funding in highly specialized areas.Mark Gannott, an economist and pharmacoeconomist, has a scholarly background in neuroscience and economics. His career took a pivotal turn following a personal tragedy that shifted his focus from medical school to the financing side of healthcare. With a side project in managing a massively popular social media page focused on dogs and mental health, Mark works on critical health issues, including cannabis economics and underfunded areas like endometriosis. His drive to bring more financial resources to women's health startups sets him apart as a thought leader in this space.In this enlightening conversation, Mark explores why women's health is still struggling to garner sufficient funding despite its massive economic potential. He talks about his work as a pharmacoeconomist and the significance of building financial models that make compelling cases for investment in women's health. Additionally, the episode highlights the importance of network analysis in connecting the right people to foster successful startups. Whether you're an investor, an entrepreneur, or someone passionate about women's health, this episode provides crucial insights into an often-overlooked yet vital sector. Mark's forward-thinking approach to financing and network building makes this episode a must-listen for anyone interested in transforming the landscape for women's health. To get the latest from Mark Gannott, you can follow him below!LinkedIn - https://www.linkedin.com/in/markgannott/ Sign up for Marcia's newsletter to receive tips and the latest on Angel Investing!Website: www.marciadawood.comLearn more about the documentary Show Her the Money: www.showherthemoneymovie.comAnd don't forget to follow us wherever you are!Apple Podcasts: https://pod.link/1586445642.appleSpotify: https://pod.link/1586445642.spotifyLinkedIn: https://www.linkedin.com/company/angel-next-door-podcast/Instagram: https://www.instagram.com/theangelnextdoorpodcast/TikTok: https://www.tiktok.com/@marciadawood

Listen now to this CME-accredited podcast, part of the Multiple Myeloma Task Force series, where we will explore strategies for mitigating disease burden and addressing health care disparities in patients with relapsed/refractory multiple myeloma. This session brings together expert insights from Task Force Co-Chairs, Dr. Sikander Ailawadhi, Professor of Medicine at Mayo Clinic, and Dr. Rahul Banerjee, Assistant Professor of Medical Oncology at Fred Hutchinson Cancer Center and the University of Washington. Their consensus-driven perspectives will provide valuable guidance on improving patient outcomes and equity in care for multiple myeloma. To learn more about the task force, read the position statement or revisit the youtube live please visit: https://i3health.com/course-information/podcast-rrmm

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CRE865. CME/MOC/AAPA credit will be available until June 19, 2025.Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understanding Disease Burden, Diagnosing Early, and Looking Toward New Management Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Insmed.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CRE865. CME/MOC/AAPA credit will be available until June 19, 2025.Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understanding Disease Burden, Diagnosing Early, and Looking Toward New Management Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Insmed.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CRE865. CME/MOC/AAPA credit will be available until June 19, 2025.Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understanding Disease Burden, Diagnosing Early, and Looking Toward New Management Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Insmed.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CRE865. CME/MOC/AAPA credit will be available until June 19, 2025.Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understanding Disease Burden, Diagnosing Early, and Looking Toward New Management Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Insmed.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CRE865. CME/MOC/AAPA credit will be available until June 19, 2025.Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understanding Disease Burden, Diagnosing Early, and Looking Toward New Management Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Insmed.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CRE865. CME/MOC/AAPA credit will be available until June 19, 2025.Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understanding Disease Burden, Diagnosing Early, and Looking Toward New Management Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Insmed.Disclosure information is available at the beginning of the video presentation.

This podcast brought to you Healthy Male is in association with Men's Health Week, June 10 - June 16 2024. A/Prof Tim Moss discusses what is impacting the health and wellbeing of Australian men and how we can support males to adopt healthy behaviours. Visit https://medcast.com.au/education/healthy-male for episode notes and more free education resources.

Dr. Joshua Wechsler and Prof. Arjan Bredenoord discuss the burden of disease in patients with EoE, the impact on quality of life, and how to overcome challenges in identifying EoE. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Arjan Bredenoord, MD, PhD (Adult Gastroenterologist): Professor, Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, the Netherlands Joshua Wechsler, MD, MSci (Pediatric Gastroenterologist): Attending Physician, Division of Gastroenterology, Hepatology & Nutrition; Campaign Urging Research for Eosinophilic Disorders (CURED) Foundation Research Scholar; Medical Director, Eosinophilic Gastrointestinal Disorders Program; Assistant Professor in Pediatrics & Medicine, Northwestern University – The Feinberg School of Medicine © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2304791 - 1.0 - 05/2024 MAT-US-2404998 v1.0  - P Expiration Date: 05/15/2026

In 2021 on Episode 13, Vor Bio's President and CEO, Dr. Robert Ang shared data about the company's lead engineered hematopoietic cell (eHSC) product candidate. Dr. Ang is back to talk to Cell & Gene: The Podcast Host, Erin Harris, about how Vor has treated 8 patients demonstrating clinical proof of concept and is also in the clinic with a CAR-T that could be used in combination with shielded stem cell transplants. They also talk through Vor's decision to build an internal cell therapy manufacturing facility co-located with their Cambridge, MA-based headquarters.

No seu trigésimo oitavo episódio, o Estudos Medievais recebe Gabriel Cordeiro, doutorando pela Universidade de São Paulo, para uma conversa sobre a primeira pandemia de peste, também conhecida como Peste Justiniana. O pesquisador aborda questões biológicas da peste, incluindo sua forma de propagação, o agente patogênico e os sintomas associados à doença. Além disso, explora os primeiros relatos da manifestação da doença. Por fim, discute as interpretações mais recentes dos historiadores sobre o impacto dessa pandemia na região do Mediterrâneo. Participantes Carolina Santos Gabriel Cordeiro Membros da equipe ⁠⁠⁠⁠⁠⁠Carolina⁠ Santos (edição)⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠Cecília Silva (edição)⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠Diego Pereira (roteiro)⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠Eric Cyon (edição)⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Gabriel Cordeiro (ilustração)⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Isabela Silva (roteiro)⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠José Fonseca (roteiro)⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠Marina Sanchez (roteiro)⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Rafael Bosch (roteiro)⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sara Oderdenge (roteiro) Recomendações bibliográficas GREEN, Monica H. Climate and Disease in Medieval Eurasia. In: LUDDEN, David. Oxford Research Encyclopedia of Asian History. Nova Iorque: Oxford University Press, 2018. MORDECHAI, Lee; EISENBERG, Merle; NEWFIELD, Timothy; IZDEBSKI, Adam, KAY, Janet; POINAR, Hendrik. The Justinianic Plague: An Inconsequential Pandemic? Proceedings of the National Academy of Sciences, v. 116, n. 51, p. 25546-25554, 2019 NEWFIELD, Timothy. Mysterious and Mortiferous Clouds: The Climate Cooling and Disease Burden of Late Antiquity. in: IZDEBSKI, Adam; MULRYAN, Michael (Eds.). Environment and Society in the Long Late Antiquity. Leiden: Brill, p. 89-115, 2018. SARRIS, Peter. New Approches to the ‘Plague of Justinian'. Past & Present, v. 254, n. 1, p. 315-346, 2022. WIECHMANN, Ingrid; GRUPE, Gisela. Detection of Yersinia pestis DNA in two early medieval skeletal finds from Aschheim (Upper Bavaria, 6th century A.D.). American Journal of Physical Anthropology, v. 126, n. 1, p. 48–55, 2004.

As Women's History Month comes to its final week, today's podcast sees web editor Nicole Raleigh in conversation with Debra Weiss, COO of the Bill & Melinda Gates Medical Research Institute (Gates MRI), discussing her role as a female leader in the leader and the non-profit organisation's work in developing novel biomedical interventions and lessening the burden of disease in LMICs.

In this opening conversation on MASLD disease burden, Zobair Younossi summarizes and expands on some key points from the recent Diabetes Spectrum review article he co-authored with Linda Henry.Zobair starts by discussing the recent review article, Understanding the Burden of Non-Alcoholic Fatty Liver Disease: Time for Action which he describes as "a summary of a large body of evidence that's being generated." He points to three pivotal issues:The treatment burden associated with MASLD and MASH is extremely high and will grow over time. The prevalence of MASLD in the overall population has grown to ~38%, but for Type 2 diabetics, who have worse outcomes associated with MASLD, this number is 68%. MASH numbers are estimated to be 5-7% in the general population, but 37% among T2D patients. As diabetes increases across the globe, these rates will go higher.The humanistic burden, as measured in Quality of Life scores, is also significant. Patients living with MASLD and MASH report lower QoL scores, which translates not only into a less happy, more depressed society, but also into significant indirect economic effects due to poorer worker performance and, presumably, more time away from work. The economic burden of MASLD is significant in every country, but the scale and structure of this burden varies from country to country. Key drivers include dietary issues and inactivity, and issues are becoming more pronounced globally. These economic issues are driven largely by the key downstream sequelae. The leading causes of death from MASLD are cardiovascular disease and extrahepatic cancers, which are costly, and patients with cirrhosis are highly susceptible to liver cancer as well. Jörn Schattenberg joins the conversation to commend Zobair on his work, which, as Jörn puts it,  "educate[s] us as physicians on where the risk factors and the at-risk populations are, and we're moving that way. I mean, we're trying to focus on patients with diabetes that are more advanced from the hepatologist perspective." He also discusses the ongoing effort to educate endocrinologists and primary care about these issues as well, since those two specialties treat the lion's share of diabetic patients. Zobair goes on to describe the Markov models of disease cost his group has built already in seven countries, and plans to build in more. Key point: MASLD is costly everywhere, but the structure of cost and, most importantly, public health solutions will vary from country to country.

Initially, this conversation focuses on how cost-effectiveness issues relate to the MASLD Disease Burden. In the process, Zobair Younossi provides education on some of the metrics and concepts pivotal to drug value assessment.Roger Green starts off asking how the economics of treating MASH stack up against hypercholesterolemia at the birth of statins in the 1980s, where the medical benefit was clear but economic was harder to manage. Zobair proceeds to describe the process by which the cost effectiveness of drugs is measured, computation of Quality Adjusted Life Years, or QALYs, and how different countries vary in the level of QALYs they consider cost effective. He also notes that within the US, at least, we may be willing to accept five times greater cost per QALY than for another. He also points out that cost effectiveness grows as new therapeutic options include price competition into a market.Louise Campbell shares the specific US cost numbers from Zobair's article, which she describes as “frightening,” particularly given the rate of growth in the disease and society's lack of efficacy in shifting the curve on this. Zobair responds by saying that one goal of the article was to create awareness that regular surveillance of diabetic patients for MASLD could have a significant economic impact in the US. As the conversation winds down, Jörn Schattenberg comments that all this is a team effort and Zobair agrees heartily.

Season four of Getting to Know You shakes up our format with a new twist. This season, we are getting to know the amazing research that PeDRA members are doing. In our first episode, nurse practitioner, Emily Croce, PhD, MSN, APRN, CPNP-PC talks us through her 2022 Childhood Eczema Challenge grant, The Role of Outdoor Air Pollution on Disease Burden and Racial Ethnic Disparities. Learn how this project made use of existing data to reveal some key findings, the tools and methodology used in this study, and how this project is going to fuel future research into the intersection of atopic diseases and racial and ethnic disparities. You can view Emily's collaborative publication here.

Only concerted multi-disciplinary collaboration and research will stem the tide of diabetes and diabetes-linked cardiovascular disease (CVD), the latter currently the leading cause of death locally and worldwide, claiming 17,9 million lives annually1.This was the consensus among some of the world's leading cardiologists and researchers gathered at the SA Heart Association's annual congress aptly themed: ‘The Cardiac Collaboration,' which took place at the Sandton Convention Centre in Johannesburg from 26-29 October this year.On the show with Nonso Mordi, Professor Eric Klug of SA Heart Association speaks on why Collaboration is Key to addressing SA's, Diabetes-Linked cardiovascular disease burden.This show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/4432283/advertisement

Only concerted multi-disciplinary collaboration and research will stem the tide of diabetes and diabetes-linked cardiovascular disease (CVD), the latter currently the leading cause of death locally and worldwide, claiming 17,9 million lives annually1.This was the consensus among some of the world's leading cardiologists and researchers gathered at the SA Heart Association's annual congress aptly themed: ‘The Cardiac Collaboration,' which took place at the Sandton Convention Centre in Johannesburg from 26-29 October this year.On the show with Nonso Mordi, Professor Eric Klug of SA Heart Association speaks on why Collaboration is Key to addressing SA's, Diabetes-Linked cardiovascular disease burden.

Only concerted multi-disciplinary collaboration and research will stem the tide of diabetes and diabetes-linked cardiovascular disease (CVD), the latter currently the leading cause of death locally and worldwide, claiming 17,9 million lives annually1.This was the consensus among some of the world's leading cardiologists and researchers gathered at the SA Heart Association's annual congress aptly themed: ‘The Cardiac Collaboration,' which took place at the Sandton Convention Centre in Johannesburg from 26-29 October this year.On the show with Nonso Mordi, Professor Eric Klug of SA Heart Association speaks on why Collaboration is Key to addressing SA's, Diabetes-Linked cardiovascular disease burden.

This one is for the kids. Long COVID can affect anyone at any age, but growing up with a chronic illness means you are learning who you are while realising who you will never be. This one is for the epidemic survivors who are still here, still around, even though the disease that changed your life is no longer the hot topic. This one is for the people living with post-polio who were told it was all in their heads. If that sounds familiar, this one is for you too. It's for all of us. We need to talk to each other. CN: This episode contains discussions of medical disbelief and trauma. Texts mentioned in this episode: (Referenced by Katie Bourdeau): COVID Long-Haulers Canada, Statement from the Chief Public Health Officer of Canada on July 7, 2021, Prevalence of long-term effects in individuals diagnosed with COVID-19: a living systematic review Van Lier et al: Disease Burden of 32 Infectious Diseases in the Netherlands, 2007-2011 Ruth Bridgen's thesis: Postpolio syndrome—“We aren't dead yet” The Office of National Statistics March 2023 report I would like to thank the British Polio Fellowship for connecting me with Frances and Ruth. Full transcripts and references are available at www.massivelydisabled.com Please rate and review Massively Disabled on Apple Podcasts and Spotify. This helps other people find the show. You can follow the show on Instagram and Twitter @massdisabledpod Hosting, producing, and editing is done by Élaina Gauthier-Mamaril Music is by Morgan Kluck-Keil This podcast is made with the support of the Centre for Biomedicine, Self and Society, Usher Institute, at the University of Edinburgh.

Did you know that adding basal insulin to patients who remain above target despite an optimal guideline-recommended antidiabetes regimen can further reduce HbA1c levels by up to 3 percentage points? Credit available for this activity expires: 11/14/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/998367?ecd=bdc_podcast_libsyn_mscpedu

Guest: Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN Approximately 6.2 million adults in the US have heart failure (hf), and this number is projected to grow to more than 8 million by 2030. Knowing this alarming statistic, what do we need to know about the clinical characteristics of hf? Take a deep dive with Dr. Nancy Albert, associate chief nursing officer for the Office of Nursing Research and Innovation. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. SC-US-75207 3/23

Guest: Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN Approximately 6.2 million adults in the US have heart failure (hf), and this number is projected to grow to more than 8 million by 2030. Knowing this alarming statistic, what do we need to know about the clinical characteristics of hf? Take a deep dive with Dr. Nancy Albert, associate chief nursing officer for the Office of Nursing Research and Innovation. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. SC-US-75207 3/23

In this episode, hosts Drs. Jennifer Lee and Jason Silverman debrief with  Dr. Sandeep Gupta on his NASPGHAN Research Year in Review.  Dr. Gupta is Professor of Pediatrics at the University of Alabama He is also the North American Editor and Chief for both JPGN and JPGN Reports.  Learning Objectives:Review impactful clinical research papers in eosinophilic gastrointestinal disorders, celiac disease, and inflammatory bowel disease from 2023Review impactful clinical research papers in hepatology from 2023 Review impactful clinical research papers in nutrition and obesity medicine from 2023Executive Summary: Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity - PubMed (nih.gov)Once-Weekly Semaglutide in Adolescents with Obesity - PMC (nih.gov) Analysis of INSPPIRE-2 Cohort: Risk Factors and Disease Burden in Children With Acute Recurrent or Chronic Pancreatitis - PubMed (nih.gov)Pancreatitis-Associated Medication Use in Hospitalized Pediatric and Young Adult Patients With Acute Pancreatitis - PubMed (nih.gov)International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature - PubMed (nih.gov)A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions - PubMed (nih.gov)Clinical guidance for the use of dupilumab in eosinophilic esophagitis: A yardstick - PubMed (nih.gov)A multisociety Delphi consensus statement on new fatty liver disease nomenclature - PubMed (nih.gov)Gut enterochromaffin cells drive visceral pain and anxiety | NatureSupport the showMerch website As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Follow us on Twitter, Facebook and Instagram for all the latest news and upcoming episodes! Support the show As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Follow us on Twitter, Facebook and Instagram for all the latest news and upcoming episodes!

“We've come in with an offering that's broader and deeper than a lot of data aggregators, but on top of that we've built really simple software that allows people in a no-code sort of way to just ask questions that they can get answers to instantly, and that's why we're winning,” Komodo Health cofounder and CEO Arif Nathoo explains. In this episode of the Vanguards of Health Care podcast, Nathoo sits down with Bloomberg Intelligence analyst Jonathan Palmer for a detailed discussion on the origins of Komodo's data and analytics platform, the nuances that differentiate it for enterprise customers and the power of its longitudinal Healthcare Map database.See omnystudio.com/listener for privacy information.

Part 5: Audience Questions & Answers: Managing NAFLD and NASH in People with T2 Diabetes: Disease Burden • Diagnosis • Current & Emerging Armamentarium with all Faculty

Part 4: Case Studies in Screening, Diagnosis & Management of NAFLD and NASH: Managing NAFLD and NASH in People with T2 Diabetes: Disease Burden • Diagnosis • Current & Emerging Armamentarium with Davida F. Kruger, MSN, APN-BC, BC-ADMNP

Part 3: Current Therapies and Novel Therapeutic Phase 3 Data: Managing NAFLD and NASH in People with T2 Diabetes: Disease Burden • Diagnosis • Current & Emerging Armamentarium with Juan Pablo Frías, MD

Part 2: Clinical Practice Guidelines for the Management of NAFLD: Understanding the Rationale for Screening 'High Risk' Patients: Managing NAFLD and NASH in People with T2 Diabetes: Disease Burden • Diagnosis • Current & Emerging Armamentarium with Kenneth Cusi, MD, FACP, FACE

Part 1: Worldwide Burden of NAFLD: Time for Action: Managing NAFLD and NASH in People with T2 Diabetes: Disease Burden • Diagnosis • Current & Emerging Armamentarium with Prof Michael Roden, MD

In honour of International NASH Day, the final episode of EASL Studio season 4 is shedding light on non-alcoholic steatohepatitis (NASH), a disease with increasing global prevalence but low awareness.FacultyZobair Younossi (Moderator)Alina M. Allen (Faculty)Sven Francque (Faculty)Vincent Wong (Faculty)Shira Zelber-Sagi (Faculty)All EASL Studio Podcasts are available on EASL Campus.

In a study recently published in “ACR Open Rheumatology” titled: “Geographic Variation in Disease Burden and Mismatch in Care of Patients With Rheumatoid Arthritis in the United States“, first author Dr. Sharon Dowell set out to understand some of the factors associated with regional variation of rheumatoid arthritis in the United States. Sharon Dowell, MD presents her study's findings and conclusions. ACR's RISE Team member, Tracy Johansson, MS, joins us as well to discuss how RISE attempts to close these gaps. Together, both of our guests help us to understand how geographic location contributes to a disproportionate level of care for those with RA and what we can do about it. 

New analysis from the Australian Institute of Health and Welfare explored what could happen if Australians reduced their body mass index or were more physically active between 2018 and 2030. It found that small improvements could have a big effect on the disease burden attributable to being overweight and inactive. But medical experts warn the government is not doing enough to encourage Australians to make healthy choices. - Het Australian Institute of Health and Welfare heeft onderzocht wat er zou kunnen gebeuren als Australiërs hun BMI ofwel hun body mass index zouden verlagen of fysiek meer actief zouden worden tussen 2018 en 2030. Uit de analyse blijkt dat kleine verbeteringen een groot effect kunnen hebben op de ziektelast door overgewicht en inactiviteit. Medische experts waarschuwen dat de regering Australiërs niet genoeg aanmoedigt gezonde keuzes te maken.

Angela R. Branche, MD, FIDSA, and Laura P. Hurley, MD, MPH, discuss research on PCPs' perceptions of RSV disease burden; current RSV testing practices; and potential barriers to adoption of any RSV vaccine.

In this podcast, an experienced conference and webinar moderator is joined by two doctors in the field of paediatric infectious diseases: David Greenberg and Maria Hemming-Harlo. In this podcast, our guest experts provide information and their perspectives on the following topics: The disease burden of rotavirus The related morbidity and mortality of rotavirus How rotavirus is transmitted The clinical picture of rotavirus infection The evidence supporting routine vaccination with RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalent) This podcast was funded by Merck Sharp & Dohme LLC. Below please find the reference list for Vax Voices, Podcast 1: The Global Burden of Rotavirus Disease and Evidence Supporting Routine Vaccination With RotaTeq to ensure listeners can further explore the content discussed. View the product information and indication for RotaTeq here. View the Select Safety Information from MSD below. Select Safety Information RotaTeq should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine. Infants with a history of intussusception or who have congenital malformation of the gastrointestinal tract that could predispose infants to intussusception should not receive RotaTeq. Infants with Severe Combined Immunodeficiency Disease or SCID should not receive RotaTeq. Administration of RotaTeq should be postponed in infants suffering from acute severe febrile illness. The presence of a minor infection is not a contraindication for immunisation. The administration of RotaTeq should be postponed in subjects suffering from acute diarrhoea or vomiting. No safety or efficacy data are available from clinical trials regarding the administration of RotaTeq to infants who are potentially immunocompromised. Cases of gastroenteritis associated with vaccine virus have been reported post marketing in infants with severe combined immunodeficiency. Vaccine virus transmission from vaccine recipient to nonvaccinated contacts has been reported. Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts. In post-marketing experience, intussusception (including death) and Kawasaki disease have been reported in infants who have received RotaTeq. As a precaution, healthcare professionals should follow-up on any symptoms indicative of intussusception (severe abdominal pain, persistent vomiting, bloody stools, abdominal bloating and/or high fever) since data from observational studies indicate an increased risk of intussusception, mostly within 7 days after rotavirus vaccination. Parents/guardians should be advised to promptly report such symptoms to their healthcare provider. The level of protection provided by RotaTeq is based on the completion of all 3 doses. As with any vaccine, vaccination with RotaTeq may not result in complete protection in all recipients. HQ-ROT-00133 | 02/23   Podcast References: 1.Nelson R. COVID-19 disrupts vaccine delivery. Lancet Infect Dis. 2020;20(5):546. 2.Centers for Disease Control and Prevention (CDC). Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Chapter 19: Rotavirus. Available at: https://www.cdc.gov/vaccines/pubs/pinkbook/rota.html. Last accessed: 6 March 2023. 3.Dormitzer PR. "Rotaviruses," Mandell GL, et al, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier Saunders; 2019:1983-96. 4.Centers for Disease Control and Prevention (CDC). Rotavirus. Clinical information. 2021. Available at: https://www.cdc.gov/rotavirus/clinical.html. Last accessed: 13 October 2022. 5.Troeger C et al. Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years. JAMA Pediatr. 2018;172(10):958-965. Erratum in: JAMA Pediatr. 2022;176(2):208. 6.GBD Diarrhoeal Diseases Collaborators. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17(9):909-948. Erratum in: Lancet Infect Dis. 2017 Sep;17(9):897. 7.Van Damme P et al. Rotavirus vaccines: considerations for successful implementation in Europe. Lancet Infect Dis. 2006;6(12):805-12. 8.Paul MO, Erinle EA. Influence of humidity on rotavirus prevalence among Nigerian infants and young children with gastroenteritis. J Clin Microbiol. 1982;15(2):212-5. 9.Finnish Institute for Health and Welfare. Infectious diseases and vaccines: rotavirus vaccine. 2020. Available at: https://thl.fi/en/web/infectious-diseases-and-vaccinations/vaccines-a-to-z/rotavirus-vaccine. Last accessed: 16 September 2022. 10.GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-71. 11.Franco MA et al. Immunity and correlates of protection for rotavirus vaccines. Vaccine. 2006;24(15):2718-31. 12.Gentsch JR et al. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis. 2005;192(Suppl 1):S146-59. 13.Merck & Co. RotaTeq®. Prescribing information. 2022. Available at: https://www.merck.com/product/usa/pi_circulars/r/rotateq/rotateq_pi.pdf. Last accessed: 4 January 2023. 14.European Medicine Agency (EMA). RotaTeq. Summary of product characteristics. 2022. Available at: https://www.ema.europa.eu/en/documents/product-information/rotateq-epar-product-information_en.pdf. Last accessed: 4 January 2023. 15.Velasquez-Portocarrero DE et al. Head-to-head comparison of the immunogenicity of RotaTeq and Rotarix rotavirus vaccines and factors associated with seroresponse in infants in Bangladesh: a randomised, controlled, open-label, parallel, phase 4 trial. Lancet Infect Dis. 2022;22(11):1606-16. 16.Cortese MM, Parashar UD; Centers for Disease Control and Prevention (CDC). Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2009;58(RR-2):1-25. 17.Vesikari T et al.; Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23-33. 18.Vesikari T et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). Int J Infect Dis. 2007;11(Suppl 2):S29-35. 19.Heyse JF; REST Study Team. Evaluating the safety of a rotavirus vaccine: the REST of the story. Clin Trials. 2008;5(2):131-9. 20.World Health Organization (WHO). Rotavirus vaccines: WHO position paper. Wkly Epidemiol Rec. 2021;96(28):301-20.  

Angela R. Branche, MD, FIDSA, and Laura P. Hurley, MD, MPH, continue their discussion of the history, epidemiology, clinical burden, morbidity, and mortality of RSV in adults, particularly in vulnerable subgroups such as older adults or adults with cardiopulmonary conditions.

On this episode, Dr. Kevin Kuo and Laurice Levine are recording in New Orleans where they take an existential dive into the concept of “disease burden” in Thalassemia. SHOW DESCRIPTION Thal Pals: The Alpha Beta Revolution Podcast is intended for patients, caregivers, providers, and the greater community of people who are impacted by Thalassemia.  Each episode, Thal Pals strives to provide listeners with critical education, the latest scientific updates, and voices from the Thalassemia community.   TRANSPARENCY STATEMENT  Thal Pals: The Alpha Beta Revolution Podcast is made possible by Agios Pharmaceuticals Inc. Visit Agios.com to learn more. The following Agios-supported programs are intended for informational and educational purposes only and are not intended as medical advice. Please speak with your healthcare professional before making any treatment decisions. Hosts and guest featured in this episode have been compensated for their time.  

Laura P. Hurley, MD, MPH, and Angela R. Branche, MD, FIDSA, discuss the history, epidemiology, clinical burden, morbidity, and mortality of RSV in adults, particularly in vulnerable subgroups such as older adults or adults with cardiopulmonary conditions.

Rose Eveleth is a futurologist – a title they prefer over the serious nature of the label “futurist.” They're the creator of a podcast network that demystifies the future, were recently featured on Netflix's The Future of Everything & a writer who explores how humans tangle with science & tech. In this episode, we explore (with much hilarity) the ethics & impacts of future technology including smart cities, artificial intelligence & data privacy.If you liked this episode, you'll also like episode 118: GMO MOSQUITOES?! ETHICS, DISEASE BURDEN & THE FUTUREGuest: https://www.instagram.com/roseveleth/ | https://www.linkedin.com/in/rose-eveleth-61759116/ | https://twitter.com/roseveleth | https://roseveleth.com/Host:  https://www.meredithforreal.com/  | https://www.instagram.com/meredithforreal/  | meredith@meredithforreal.com | https://www.youtube.com/meredithforreal  | https://www.facebook.com/meredithforrealthecuriousintrovertSponsors: https://uwf.edu/university-advancement/departments/historic-trust/ | https://www.ensec.net/

CME credits: 1.25 Valid until: 21-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/amkd-disease-burden-and-management-strategies-the-need-for-small-molecule-treatments/14538/ This program discusses the need to increase awareness about APOL1-Mediated Kidney Disease (AMKD), the clinical impact of genotyping for early diagnosis, disease management, and the need for new small-molecule drug treatments. There is currently a lack of awareness among key decision-makers and in the Black community regarding the health disparities and the importance of genotyping in AMKD. Increasing awareness among nephrologists, hospitalists, geneticists, and patient communities on the impact of early genotyping for APOL1 in Black patients have the potential to improve outcomes and reduce health disparities. Moreover, increasing awareness among nephrologists and patient networks may improve clinical trial participation among underrepresented communities, which can directly impact the development of new AMKD treatments.

Comorbidities in Axial Spondyloarthritis Dr. Antoni Chan discusses Abstract 1609 at ACR22 Convergence. Diffuse alveolar hemorrhage in antiphospholipid syndrome Dr. Eric Dein discusses Abstract 0675 at ACR22 Convergence. Abstract 0675: Clinical Characteristics and Factors Associated with Relapse and Mortality in Diffuse Alveolar Hemorrhage Among Patients with Antiphospholipid Syndrome: A Multi-Center Retrospective Cohort Eosinophilia in systemic JIA patients after exposure to biologics Dr. Bella Mehta discusses Abstract 0872 at ACR22 Convergence. Abstract 0872: Incidence, Risk Factors, and Outcomes of Eosinophilia on IL-1 and IL-6 Inhibitors in Systemic and Non-Systemic Juvenile Idiopathic Arthritis Gender differences in Axial Spondyloarthritis Dr. Antoni Chan covered abstracts 0497 and 1614 at ACR22 Convergence in Philadelphia, PA. Inadequate Dosing of Hydroxychloroquine Leads to Hospitalizations in SLE Dr. Sheila Reyes discusses abstract 1654 at ACR22 Convergence.  Abstract 1654: Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares Oligoarticular PsA: FOREMOST Study Dr. Peter Nash discusses abstract 1018 at ACR22 Convergence.  Abstract 1018: Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis: Results from the Ongoing FOREMOST Study Sensor-engineered glove evaluates hand function in RA Dr. David Liew discusses abstract 0904 at ACR22 Convergence.  Abstract 0904: Testing the Hand Function with a Sensor-engineered Glove in Patients with Rheumatoid Arthritis

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.09.27.509283v1?rss=1 Authors: Fongang, B., Satizabal, C. L., Kautz, T. F., Ngouongo, Y. W., SherraeMuhammad, J. A., Vasquez, E., Mathews, J., Goss, M., Saklad, A. R., Himali, J., Beiser, A., Cavazos, J. E., Mahaney, M. C., Maestre, G., DeCarli, C., Shipp, E. L., Vasan, R. S., Seshadri, S. Abstract: A bidirectional communication exists between the brain and the gut, in which the gut microbiota influences cognitive function and vice-versa. Gut dysbiosis has been linked to several diseases, including Alzheimer's disease and related dementias (ADRD). However, the relationship between gut dysbiosis and markers of cerebral small vessel disease (cSVD), a major contributor to ADRD, is unknown. In this cross-sectional study, we examined the connection between the gut microbiome, cognitive, and neuroimaging markers of cSVD in the Framingham Heart Study (FHS). Markers of cSVD included white matter hyperintensities (WMH), peak width of skeletonized mean diffusivity (PSMD), and executive function (EF), estimated as the difference between the trail-making tests B and A. We included 972 FHS participants with MRI scans, neurocognitive measures, and stool samples and quantified the gut microbiota composition using 16S rRNA sequencing. We used multivariable association and differential abundance analyses adjusting for age, sex, BMI, and education level to estimate the association between gut microbiota and WMH, PSMD, and EF measures. Our results suggest an increased abundance of Pseudobutyrivibrio and Ruminococcus genera was associated with lower WMH and PSMD (p-values less than 0.001), as well as better executive function (p-values less than 0.01). In addition, in both differential and multivariable analyses, we found that the gram-negative bacterium Barnesiella intestinihominis was strongly associated with markers indicating a higher cSVD burden. Finally, functional analyses using PICRUSt implicated various KEGG pathways, including microbial quorum sensing, AMP/GMP-activated protein kinase, phenylpyruvate, and {beta}-hydroxybutyrate production previously associated with cognitive performance and dementia. Our study provides important insights into the association between the gut microbiome and cSVD, but further studies are needed to replicate the findings. Copy rights belong to original authors. Visit the link for more info Podcast created by PaperPlayer

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. The Managed Care Implications of Cost, Disease Burden, and Quality of Life in Myelofibrosis   Educational Objective: Recognize the quality-of-life impacts and cost of therapy challenges patients with myelofibrosis face and explore strategies available to better manage this diagnosis.       Melissa Pozotrigo, PharmD, BCOP Senior Clinical Pharmacist OncoHealth Atlanta, Georgia   Melissa Pozotrigo, PharmD, BCOP, has no financial relationships with commercial interests to disclose.     Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-397-H01-P. The activity is available for CE credit through August 29, 2023. This activity is supported by an educational grant from Incyte Corporation. Learn more about your ad choices. Visit megaphone.fm/adchoices

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. The Managed Care Implications of Cost, Disease Burden, and Quality of Life in Myelofibrosis   Educational Objective: Recognize the quality-of-life impacts and cost of therapy challenges patients with myelofibrosis face and explore strategies available to better manage this diagnosis.       Melissa Pozotrigo, PharmD, BCOP Senior Clinical Pharmacist OncoHealth Atlanta, Georgia   Melissa Pozotrigo, PharmD, BCOP, has no financial relationships with commercial interests to disclose.     Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-397-H01-P. The activity is available for CE credit through August 29, 2023. This activity is supported by an educational grant from Incyte Corporation. Learn more about your ad choices. Visit megaphone.fm/adchoices

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. The Managed Care Implications of Cost, Disease Burden, and Quality of Life in Myelofibrosis   Educational Objective: Recognize the quality-of-life impacts and cost of therapy challenges patients with myelofibrosis face and explore strategies available to better manage this diagnosis.       Melissa Pozotrigo, PharmD, BCOP Senior Clinical Pharmacist OncoHealth Atlanta, Georgia   Melissa Pozotrigo, PharmD, BCOP, has no financial relationships with commercial interests to disclose.     Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-397-H01-P. The activity is available for CE credit through August 29, 2023. This activity is supported by an educational grant from Incyte Corporation. Learn more about your ad choices. Visit megaphone.fm/adchoices

Meredith Danberg-Ficarelli is a  zero waste consultant and executive director of Common Ground Compost, a New York organization dedicated to waste reduction through zero waste program design, staff training, education, advocacy, collection & compost. Here she explains how trash & recycling really work, the socioeconomic dynamics in environmental causes & how we can be less trashy.If you liked this episode, you'll also like episode 118: GMO MOSQUITOES?! ETHICS, DISEASE BURDEN & THE FUTUREGuest: https://www.linkedin.com/in/meredithdf/ | https://www.instagram.com/_garbagequeen_/ | https://www.instagram.com/commoncompost/ | https://www.facebook.com/commongroundcompost | https://commongroundcompost.com/ Host:  https://www.meredithforreal.com/  | https://www.instagram.com/meredithforreal/  | meredith@meredithforreal.com | https://www.youtube.com/meredithforreal  | https://www.facebook.com/meredithforrealthecuriousintrovertSponsors: Watch me on TV https://bit.ly/3ImiTat |   https://uwf.edu/university-advancement/departments/historic-trust/ | https://www.ensec.net/

The pandemic has been a global issue, which has benefitted from the coming together of industry, pharma, academia, non-governmental and governmental support. What the pandemic has also brought into sharp focus is the global imbalance access to healthcare and health inequity between the Global North and Global South. For this important conversation, we are joined by Professor Linda-Gail Bekker, Chief Operating Officer of the Desmond Tutu HIV Foundation about the current situation with HIV and TB in Africa, and the impact COVID-19 has had on patients already suffering from communicable diseases. So, what can we do? Lenias Hwenda, founder and CEO of Medicines for Africa, explains the additional problems of access to medicines and potential solutions for global vaccine inequity, working to make medicines as inexpensive as possible, and improving the supply chain. Related reading – Dzau, V.J., Balatbat, C.A., Offodile II, A.C., Closing the global vaccine equity gap: equitably distributed manufacturing. The Lancet. 2022;399(10339): 1924-1926. DOI: https://doi.org/10.1016/S0140-6736(22)00793-0 The Global Biopharma Resilience Index How localizing manufacturing is helping the Middle East take control of its vaccine supply? Keywords: equitable access, HIV, human immunodeficiency viruses, Lentivirus, medicines, pandemic, countries, vaccine, TB, epidemic, Africa, supply chain, communicable diseases, middle-income countries, access, low-income countries, Global North, Global South, disease burden.

In April of 2021, GMO mosquitos were released in the Florida Keys, but as Molecular Biologist, Dr. Natalie Kofler explains, they have been released in other regions prior to that. She helps shed light on the difference between GMO mosquitos and gene drive mosquitoes & the global impact of diseases spread by mosquitoes. We also take a deep dive into the ethical questions around who is creating these lab-altered insects & who is impacted by their release into the wild.Guest: https://www.editingnature.org/  |  https://twitter.com/nataliekofler  |  https://twitter.com/EditingNatureHost:  https://www.meredithforreal.com/  | https://www.instagram.com/meredithforreal/  | meredith@meredithforreal.com | https://www.youtube.com/meredithforreal  | https://www.facebook.com/meredithforrealthecuriousintrovertSponsors: https://uwf.edu/university-advancement/departments/historic-trust/ | https://www.ensec.net/

Go online to PeerView.com/CQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in attention-deficit/hyperactivity disorder (ADHD) discuss overcoming challenges in the recognition and management of adult ADHD in primary care. Upon completion of this CE activity, participants will be able to: Evaluate the association between attention-deficit/hyperactivity disorder (ADHD) symptoms and functional impairment in adulthood, Utilize evidence-based tools to identify and diagnose adult ADHD, Engage in shared decision-making to optimize ADHD treatment selection and management considering the latest clinical evidence as well as the patient's ADHD symptoms, psychiatric and medical comorbidities, and individual preferences.

Go online to PeerView.com/CQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in attention-deficit/hyperactivity disorder (ADHD) discuss overcoming challenges in the recognition and management of adult ADHD in primary care. Upon completion of this CE activity, participants will be able to: Evaluate the association between attention-deficit/hyperactivity disorder (ADHD) symptoms and functional impairment in adulthood, Utilize evidence-based tools to identify and diagnose adult ADHD, Engage in shared decision-making to optimize ADHD treatment selection and management considering the latest clinical evidence as well as the patient's ADHD symptoms, psychiatric and medical comorbidities, and individual preferences.

Go online to PeerView.com/CQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in attention-deficit/hyperactivity disorder (ADHD) discuss overcoming challenges in the recognition and management of adult ADHD in primary care. Upon completion of this CE activity, participants will be able to: Evaluate the association between attention-deficit/hyperactivity disorder (ADHD) symptoms and functional impairment in adulthood, Utilize evidence-based tools to identify and diagnose adult ADHD, Engage in shared decision-making to optimize ADHD treatment selection and management considering the latest clinical evidence as well as the patient's ADHD symptoms, psychiatric and medical comorbidities, and individual preferences.

Go online to PeerView.com/CQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in attention-deficit/hyperactivity disorder (ADHD) discuss overcoming challenges in the recognition and management of adult ADHD in primary care. Upon completion of this CE activity, participants will be able to: Evaluate the association between attention-deficit/hyperactivity disorder (ADHD) symptoms and functional impairment in adulthood, Utilize evidence-based tools to identify and diagnose adult ADHD, Engage in shared decision-making to optimize ADHD treatment selection and management considering the latest clinical evidence as well as the patient's ADHD symptoms, psychiatric and medical comorbidities, and individual preferences.

Go online to PeerView.com/CQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in attention-deficit/hyperactivity disorder (ADHD) discuss overcoming challenges in the recognition and management of adult ADHD in primary care. Upon completion of this CE activity, participants will be able to: Evaluate the association between attention-deficit/hyperactivity disorder (ADHD) symptoms and functional impairment in adulthood, Utilize evidence-based tools to identify and diagnose adult ADHD, Engage in shared decision-making to optimize ADHD treatment selection and management considering the latest clinical evidence as well as the patient's ADHD symptoms, psychiatric and medical comorbidities, and individual preferences.

Go online to PeerView.com/CQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in attention-deficit/hyperactivity disorder (ADHD) discuss overcoming challenges in the recognition and management of adult ADHD in primary care. Upon completion of this CE activity, participants will be able to: Evaluate the association between attention-deficit/hyperactivity disorder (ADHD) symptoms and functional impairment in adulthood, Utilize evidence-based tools to identify and diagnose adult ADHD, Engage in shared decision-making to optimize ADHD treatment selection and management considering the latest clinical evidence as well as the patient's ADHD symptoms, psychiatric and medical comorbidities, and individual preferences.

Go online to PeerView.com/CQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in attention-deficit/hyperactivity disorder (ADHD) discuss overcoming challenges in the recognition and management of adult ADHD in primary care. Upon completion of this CE activity, participants will be able to: Evaluate the association between attention-deficit/hyperactivity disorder (ADHD) symptoms and functional impairment in adulthood, Utilize evidence-based tools to identify and diagnose adult ADHD, Engage in shared decision-making to optimize ADHD treatment selection and management considering the latest clinical evidence as well as the patient's ADHD symptoms, psychiatric and medical comorbidities, and individual preferences.

Go online to PeerView.com/CQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in attention-deficit/hyperactivity disorder (ADHD) discuss overcoming challenges in the recognition and management of adult ADHD in primary care. Upon completion of this CE activity, participants will be able to: Evaluate the association between attention-deficit/hyperactivity disorder (ADHD) symptoms and functional impairment in adulthood, Utilize evidence-based tools to identify and diagnose adult ADHD, Engage in shared decision-making to optimize ADHD treatment selection and management considering the latest clinical evidence as well as the patient's ADHD symptoms, psychiatric and medical comorbidities, and individual preferences.

Host: Linda Stein Gold, MD Guest: Jonathan S. Weiss, MD When assessing the burden of psoriasis, are you looking beyond the skin? Here to share their perspectives on the burden of psoriasis are Dr. Linda Stein Gold and Jonathan Weiss. Together, they'll discuss the psychological impacts of psoriasis, how we can talk to patients, and more.

Food is our happy place, literally! Did you know that 95% of serotonin is produced in our gastrointestinal tract (G.I.)? The link between proper nutrition and good health is well-documented, yet most healthcare providers are taught very little about the natural healing power of food. Worse are the barriers between insurance providers and dieticians like our guest, Denine Rogers MS, RDN, L.D., FAND. Instead of using a proper balanced diet, exercise and nutrition to heal, we are often taught to treat patients with pharmaceuticals. Today, we speak to Denine Rogers, registered dietitian and licensed nutritionist, about the need for more black dieticians, barriers within the field, and how physicians and dieticians can work together to create a complete and individualized wellness plan. Key Takeaways: [00:01:53] Meet Denine Rogers MS, RDN, LD, FAND [00:03:49] What inspired her to become a dietitian [00:13:54] Why the culture needs more black dieticians and how to get started [00:14:04] Challenges that dieticians face and how to overcome them [00:17:44] How Denine is leading the charge to recruit more dieticians [00:23:50] Reframing weight loss to make better food choices Takeaways to help you Cure The Culture: Denine did not aspire to be a dietitian and nutritionist. It was an internship and the encouragement of Paula Sneed, the first black Senior Vice President of Global Marketing Resources & Initiatives at Kraft Foods, Inc., that exposed her to the industry. Her experience highlights the importance of mentorship in the black community. Healthy living is marketed as aspirational instead of a fundamental human right. This causes underrepresented communities to shy away from healthy lifestyle changes. In this interview, Denine explains the mental and physical roadblocks that prevent patients from experiencing the healing benefits of food and how dieticians and physicians can begin to work together.

Vascular surgeon Oliver Aalami, M.D. discusses his research in clinical validation devices, algorithms from step-count data, and health data accessibility for patients. This episode is part of a Health IT series by the AMA-MSS Committee on Health Information Technology, hosted by Kristofer Jackson, medical student at the University of Toledo College of Medicine.

CME credits: 0.25 Valid until: 30-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/future-narcolepsy-therapy-its-likely-impact-disease-burden-and-patient-outcomes/12743/ While gaps in care remain, the future is bright for patients with narcolepsy. Data from cutting-edge clinical trials were recently presented at 2021 Virtual Sleep, the 35th Annual Meeting of the Associated Professional Sleep Societies, and Drs. Clete Kushida and Michael Thorpy are ready to break it down for you. Join them as they examine the main barriers to timely diagnosis and treatment and then dive into the latest research on currently available and emerging pharmacologic therapies. Tune in to stay up to date on the latest progress and research on the management of patients with narcolepsy.

CME credits: 0.25 Valid until: 30-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/future-narcolepsy-therapy-its-likely-impact-disease-burden-and-patient-outcomes/12743/ While gaps in care remain, the future is bright for patients with narcolepsy. Data from cutting-edge clinical trials were recently presented at 2021 Virtual Sleep, the 35th Annual Meeting of the Associated Professional Sleep Societies, and Drs. Clete Kushida and Michael Thorpy are ready to break it down for you. Join them as they examine the main barriers to timely diagnosis and treatment and then dive into the latest research on currently available and emerging pharmacologic therapies. Tune in to stay up to date on the latest progress and research on the management of patients with narcolepsy.

UTIs: sex differences / antibiotics / self-diagnosis / cranberry juice / probiotics / D-mannose / drinking water / peeing after sex / contraception / topical estrogen. iPhone 12's effect on pacemakers and implanted defibrillators. COVID-19 vaccines: Johnson & Johnson's / AstraZeneca's / variants / scams.   * Jingle by Joseph Hackl * Theme music: “Fall of the Ocean Queen“ by Joseph Hackl. * Assistant researcher: Nicholas Koziris   To contribute to The Body of Evidence, go to our Patreon page at: http://www.patreon.com/thebodyofevidence/.   Patrons get a bonus show on Patreon called “Digressions”! Check it out!     References:   1) Statistics from the American Urological Association: https://www.urologyhealth.org/healthy-living/urologyhealth-extra/magazine-archives/summer-2016/understanding-utis-across-the-lifespan   2) Urinary Tract Infection Syndromes: Occurrence, Recurrence, Bacteriology, Risk Factors, and Disease Burden: https://www.sciencedirect.com/science/article/pii/S0891552013000743?via%3Dihub   3) Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women: https://pubmed.ncbi.nlm.nih.gov/11434727/   4) Antibiotic sparing strategy: https://www.bmj.com/content/351/bmj.h6544   5) Cochrane review on Cranberries for preventing urinary tract infections: https://doi.org/10.1002/14651858.CD001321.pub5   6) Cranberry Extract for Symptoms of Acute, Uncomplicated Urinary Tract Infection: A Systematic Review: https://www.mdpi.com/2079-6382/10/1/12   7) Cochrane review on Probiotics for preventing urinary tract infections in adults and children: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008772.pub2/full   8) Systematic review of the literature on D-mannose for recurrent UTIs: https://pubmed.ncbi.nlm.nih.gov/32972899/   9) Fluid intake to prevent recurrent UTIs: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584323/   10) Prevention and treatment of uncomplicated lower urinary tract infections in the era of increasing antimicrobial resistance-non-antibiotic approaches: a systemic review: https://link.springer.com/article/10.1007/s00404-019-05256-z   11) The Role of Asymptomatic Bacteriuria in Young Women With Recurrent Urinary Tract Infections: To Treat or Not to Treat? https://doi.org/10.1093/cid/cis534   12) INESSS Antibiotic Guidelines: https://www.inesss.qc.ca/fileadmin/doc/INESSS/Outils/GUO/Anglo/Guide_InfectionUrinaire_EN_WEB.pdf       Music Credits:   Joy And Optimism (loopable) by chilledmusic Link: https://filmmusic.io/song/7580-joy-and-optimism-loopable- License: https://filmmusic.io/standard-license   Long Road Ahead by Kevin MacLeod Link: https://filmmusic.io/song/3996-long-road-ahead License: https://filmmusic.io/standard-license  

The world is shutting down: travel is curtailed, socialising is taboo, shops are closed, COVID-19 has every community, globally, in a state of panic. And if there's ever a company designed to step into the void and say, “we're here to help”, it's Leidos.“Because of the depth and breadth that Leidos can bring to the table, particularly around disease surveillance, the processing of new medications, new technologies to be applied in the healthcare space, we think we're at a unique advantage to help solve many crises, but this one in particular.”Tune in and learn how Leidos is leveraging our 50+ years of helping our customers solve hard challenges, to try to unravel this particular riddle. On today's podcast:The scientific basics of the CoronavirusHow Leidos is supporting the efforts to contain COVID-19Why we should ALL be social distancingThe best practices to help limit the spread of COVID-19The different risk levels for different age groupsThe cyber security challenges coming out of the pandemic

In this special episode of What Christians Should Know, Dr. Sadaphal talks about the coronavirus (COVID-19): that is, how do we think about it, how do we make sense of it, and how do we respond biblically to the current crisis. This episode is meant to speak to people who are concerned, confused, fearful or anxious about current events. Our Scripture focus will be II Chronicles 9:23. The notes below are mentioned in the podcast: Listen to Pastor Ed Moore’s Sermon (from Sunday, March 15th, 2020 @ North Shore Baptist Church): https://www.sermonaudio.com/sermoninfo.asp?SID=315202336317658 Footnotes: 1. World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed on February 12, 2020). 2. Centers for Disease Control. Disease Burden of Influenza. https://www.cdc.gov/flu/about/burden/index.html (Accessed March 14, 2020). 3. Chan JF, Lau SK, To KK, et al. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 2015; 28:465. 4. International Committee on Taxonomy of Viruses. http://ictvonline.org/virusTaxonomy.asp (Accessed on March 14, 2020). 5. Masters PS, Perlman Masters PS, S. Coronaviridae. In: Fields Virology, 6th ed, Knipe DM, Howley PM, Cohen JI, et al (Eds), Lippincott Williams & Wilkins, a Wolters Kluwer business, Philadelphia 2013. Vol 2, p.825.   6. McIntosh K, Peiris JSM. Coronaviruses. In: Clinical Virology, 3rd ed, Richman DD, Whitley RJ, Hayden FG (Eds), ASM Press, Washington, DC 2009. p.1155.   7.  Perlman S. Pathogenesis of coronavirus-induced infections. Review of pathological and immunological aspects. Avd Exp Med Biol 1998; 440:503.

Go online to PeerView.com/DUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the management of anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia because of CKD, Compare current and emerging treatments for CKD-associated anemia in terms of their mechanisms of action, efficacy, and safety, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Go online to PeerView.com/DUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the management of anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia because of CKD, Compare current and emerging treatments for CKD-associated anemia in terms of their mechanisms of action, efficacy, and safety, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Go online to PeerView.com/DUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the management of anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia because of CKD, Compare current and emerging treatments for CKD-associated anemia in terms of their mechanisms of action, efficacy, and safety, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Go online to PeerView.com/DUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the management of anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia because of CKD, Compare current and emerging treatments for CKD-associated anemia in terms of their mechanisms of action, efficacy, and safety, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Go online to PeerView.com/DUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the management of anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia because of CKD, Compare current and emerging treatments for CKD-associated anemia in terms of their mechanisms of action, efficacy, and safety, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Go online to PeerView.com/DUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the management of anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia because of CKD, Compare current and emerging treatments for CKD-associated anemia in terms of their mechanisms of action, efficacy, and safety, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Go online to PeerView.com/DUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the management of anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia because of CKD, Compare current and emerging treatments for CKD-associated anemia in terms of their mechanisms of action, efficacy, and safety, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Go online to PeerView.com/DUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the management of anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia because of CKD, Compare current and emerging treatments for CKD-associated anemia in terms of their mechanisms of action, efficacy, and safety, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Go online to PeerView.com/DUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the management of anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia because of CKD, Compare current and emerging treatments for CKD-associated anemia in terms of their mechanisms of action, efficacy, and safety, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Go online to PeerView.com/DUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the management of anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia because of CKD, Compare current and emerging treatments for CKD-associated anemia in terms of their mechanisms of action, efficacy, and safety, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Welcome everyone to another episode of Nerds Amalgamated, we would like to take a moment and congratulate all those who are graduating university, school, or just having an excellent week. “The pursuit of knowledge is never ending. The day you stop seeking knowledge is the day you stop growing. Brandon Travis Ciaccio.” So, no we have set a serious mood let’s look at the first topic, which is that video games are an excellent way to combat loneliness. Also, that video games are helpful for men to combat issues such as social isolation and stress for men in today’s society. That’s right, read that correctly, video games are beneficial to men’s health and should be encouraged. What to know more to help develop those arguments for the girlfriend or boss, listen in and find out what we are talking about.Next up Buck has decided to bring us a mystery to try and solve. Now who doesn’t love a good puzzle? If like Buck you love sitting down with a crossword, a Sudoku or reading a good detective novel then you will love this. We have a mystery that is 500 hundred years old, has some of the most baffling elements and to top it off has stumped many professional investigators over the years. We are talking about a mass murder that struck fear in the hearts of the population of England. This is a mystery that is guaranteed to get you remembered in history if you solve it. Want to know what Buck has unveiled for us to ponder, listen in and find out.Now Ben Affleck is not someone who we get excited about, in fact he makes Buck yawn at the mere mention of his name. In fact I just yawned at the thought, crikey why are we talking about him? Well, it appears that he has a movie in the works that is looking kind of good, it is a topic that we hope he does justice to. Now we know that Hollywood has failed to deliver anything great for some time now, but this story has potential. We aren’t going to hold our breathe, and not just because of Benny boy of the sleep inducing performance. The reality is that the story is one that needs to be told with a sensitivity and care that is hard to deliver. This is something the likes of Spielberg should be directing. Want to know what it is we are talking about? You know what to do.As usual we have the regular shout outs, birthdays, remembrances, and special events. We hope you enjoy this episode and if you want to give us feedback we are always happy to hear from you. Take care of yourselves, look out for each other and stay hydrated.Video Games cure Loneliness - https://www.menshealth.com/sex-women/a29578572/men-friendships-video-games-loneliness/?fbclid=IwAR1AI07WCrmV-A7MVbqBGI5-H26VfKTj2k6fS6o3EZM6JkC0Rk_dJX9ye0ISweating disease origins - https://www.insidescience.org/news/medical-historians-still-struggle-identify-origin-disease-swept-across-england-500-years-agoBen Affleck’s new project - https://deadline.com/2019/11/ben-affleck-direct-congo-plunder-tale-king-leopolds-ghost-belgian-king-leopold-ii-1202791265/Games currently playingBuck– Spyro - https://store.steampowered.com/app/996580/Spyro_Reignited_Trilogy/Rating – 4.5/5Professor- Underrails - https://www.underrail.com/Rating – 5/5DJ – Age Of Empires Bundle - https://store.steampowered.com/bundle/11831/Age_of_Empires_Definitive_Edition_Bundle/Rating – 4/5Other topics discussedThe Elder Scrolls V: Skyrim- https://en.wikipedia.org/wiki/The_Elder_Scrolls_V:_SkyrimLAN Party (a gathering of people with computers or compatible game consoles, where a local area network (LAN) connection is established between the devices using a router or switch, primarily for the purpose of playing multiplayer video games together.)- https://en.wikipedia.org/wiki/LAN_partyLAN party go to gamesProfessorWarcraft III: Reign of Chaos - https://en.wikipedia.org/wiki/Warcraft_III:_Reign_of_ChaosHalo: Combat Evolved - https://en.wikipedia.org/wiki/Halo:_Combat_EvolvedBuckUnreal Tournament - https://en.wikipedia.org/wiki/Unreal_TournamentCall of Duty - https://en.wikipedia.org/wiki/Call_of_Duty_(video_game)DJStarcraft: Brood War - https://en.wikipedia.org/wiki/StarCraft:_Brood_WarDunbar’s Number (a suggested cognitive limit to the number of people with whom one can maintain stable social relationships—relationships in which an individual knows who each person is and how each person relates to every other person.)- https://en.wikipedia.org/wiki/Dunbar%27s_numberMacho Man Randy Savage as a Skyrim dragon- https://www.pcgamer.com/au/the-life-and-times-of-skyrims-best-dragon-macho-man-randy-savage/Tommy Wiseau Horse in Skyrim- https://bigmemes.funnyjunk.com/comments/Quotoh+hi+markquot+_78273e9f011bfc08a3d9222b3b39e3a5.jpgArthur, Prince of Wales (Prince of Wales, Earl of Chester and Duke of Cornwall.)- https://en.wikipedia.org/wiki/Arthur,_Prince_of_Wales28 Days Later (2002 British post-apocalyptic horror film directed by Danny Boyle.)- https://en.wikipedia.org/wiki/28_Days_Later28 Weeks Later (2007 horror film directed by Juan Carlos Fresnadillo. A sequel to the 2002 film 28 Days Later.)- https://en.wikipedia.org/wiki/28_Weeks_LaterIgnaz Semmelweis (Hungarian physician and scientist, now known as an early pioneer of antiseptic procedures.)- https://en.wikipedia.org/wiki/Ignaz_SemmelweisReligious restrictions on the consumption of pork- https://en.wikipedia.org/wiki/Religious_restrictions_on_the_consumption_of_porkElvis Lives (TNC Podcast)- https://thatsnotcanon.com/elvislivesShaun of the Dead (2004 horror comedy film directed by Edgar Wright, who co-wrote it with Simon Pegg.)- https://en.wikipedia.org/wiki/Shaun_of_the_DeadWarm Bodies (2013 American paranormal romantic zombie comedy film written and directed by Jonathan Levine and based on Isaac Marion's novel of the same name.)- https://en.wikipedia.org/wiki/Warm_Bodies_(film)Disease Burden (impact of a health problem as measured by financial cost, mortality, morbidity, or other indicators.)- https://en.wikipedia.org/wiki/Disease_burdenAnthrax Outbreaks (2016 Anthrax outbreak in Serbia)- https://en.wikipedia.org/wiki/List_of_anthrax_outbreaksArgo (2012 American historical drama film directed by Ben Affleck.)- https://en.wikipedia.org/wiki/Argo_(2012_film)Blood Diamond (2006 political war thriller film co-produced and directed by Edward Zwick, starring Leonardo DiCaprio, Jennifer Connelly, and Djimon Hounsou.)- https://en.wikipedia.org/wiki/Blood_DiamondLions For Lambs (2007 American war drama film directed by Robert Redford about the connection between a platoon of United States soldiers in Afghanistan, a U.S. senator, a reporter, and a California college professor.)- https://en.wikipedia.org/wiki/Lions_for_LambsThe Gunman (2015 action thriller film directed by Pierre Morel and written by Don Macpherson, Pete Travis and Sean Penn, based on the novel The Prone Gunman (French title: La position du tireur couché) by Jean-Patrick Manchette.)- https://en.wikipedia.org/wiki/The_Gunman_(2015_film)Musicals Taught Me Everything I Know (TNC Podcast)- https://thatsnotcanon.com/mtmeikDiablo (action role-playing hack and slash video game developed by Blizzard North and released by Blizzard Entertainment.)- https://en.wikipedia.org/wiki/Diablo_(video_game)Cobra Car (formerly known as Shelby Cobra, simply titled COBRA in the original game) is a cheat unit in Age of Empires II.)- https://ageofempires.fandom.com/wiki/Cobra_CarAge of Empires 1 Intro Cinematic- https://www.youtube.com/watch?v=V7LZLx_5pu0Connor McGregor vs Hafþór Júlíus Björnsson- https://www.youtube.com/watch?v=Aaehn1aY8IgJohn Titor (name used on several bulletin boards during 2000 and 2001 by a poster claiming to be an American military time traveler from 2036.)- https://en.wikipedia.org/wiki/John_TitorMax Headroom (a fictional artificial intelligence (AI) character, known for his wit and stuttering, distorted, electronically sampled voice.)- https://en.wikipedia.org/wiki/Max_Headroom_(character)Star Trek IV: The Voyage Home (1986 American science fiction film directed by Leonard Nimoy and based on the television series Star Trek.)- https://en.wikipedia.org/wiki/Star_Trek_IV:_The_Voyage_HomeStar Wars (retroactively titled Star Wars: Episode IV – A New Hope is a 1977 American epic space-opera film written and directed by George Lucas.)- https://en.wikipedia.org/wiki/Star_Wars_(film)Shoutouts26 Nov 1970 – In Basse-Terre, Guadeloupe, 1.5 inches (38.1 mm) of rain fall in a minute, the heaviest rainfall ever recorded. - https://en.wikipedia.org/wiki/Basse-Terre26 Nov 1983 - World's greatest robbery; 26 million pounds (sterling) worth of gold bullion, diamonds and cash stolen from Brink's-Mat warehouse at Heathrow Airport, England. The bullion was the property of Johnson Matthey Bankers Ltd, which collapsed the following year after making large loans to frauds and insolvent firms. Two men were convicted, and most of the gold has never been recovered. Insurers Lloyd's of London paid out for the losses. Several deaths have been linked to the case, and there are links to the Hatton Garden safe deposit burglary in April 2015. - https://en.wikipedia.org/wiki/Brink%27s-Mat_robbery26 Nov 2003 – The Concorde makes its final flight, over Bristol, England. Known as G-BOAF (216) or its call sign Concorde Alpha Foxtrot (the name comes from its official UK registration) the Concorde departed from Heathrow at 11:30 GMT, it made a last, brief, supersonic flight, carrying 100 BA staff, over the Bay of Biscay. It then flew a "lap of honour" above Bristol, passing over Portishead, Clevedon,Weston-super-Mare, Bristol Airport and Clifton Suspension Bridge, before landing at Filton, soon after 13:00 GMT. It was met by Prince Andrew, who formally accepted its handover. It had flown a total of 18,257 hours. Until 2010, the aircraft was open for public viewing at the Airbus facility; since 2017 it has been the main exhibit at Filton's Aerospace Bristol museum. - https://en.wikipedia.org/wiki/Concorde_aircraft_histories#British_production_aircraftRemembrances26 Nov 1994 – Nimrod Workman, American singer, coal miner and trade unionist. His musical repertoire included traditional English and Scottish ballads, Appalachian folk songs and original compositions. Workman was a recipient of a 1986 National Heritage Fellowship awarded by the National Endowment for the Arts, which is the United States government's highest honor in the folk and traditional arts. He died at the age of 99 in Knoxville, Tennessee. - https://en.wikipedia.org/wiki/Nimrod_Workman26 Nov 2005 – Stanley Melvin Berenstain, American author and illustrator, co-created the Berenstain Bears. Inspired by their children's enthusiasm for Dr. Seuss books, the Berenstains decided to attempt a series with animal protagonists themselves, settling on bears not because of their surname as was commonly believed, but because they found them easy to draw. They published their first book featuring the Berenstain Bears, The Big Honey Hunt, in 1962. At the time, their inspiration, Theodor Geisel (Dr. Seuss), was working as an editor in the children's division of Random House Publishing and eagerly approved the concept. He edited several books in the Berenstain Bears series and created a lasting franchise including many more books, television series, toys, and stage productions. He died from cancer at the age of 82 in Solebury Township, Pennsylvania. - https://en.wikipedia.org/wiki/Stan_and_Jan_Berenstain26 Nov 2012 – Joseph Edward Murray, American plastic surgeon who performed the first successful human kidney transplant on identical twins Richard and Ronald Herrick on December 23, 1954. Murray shared the Nobel Prize in Physiology or Medicine in 1990 with E. Donnall Thomas for their discoveries concerning "organ and cell transplantation in the treatment of human disease." Murray became an international leader in the study of transplantation biology, the use of immunosuppressive agents, and studies on the mechanisms of rejection. He died from a stroke at the age of 93 in Boston,Massachusetts. - https://en.wikipedia.org/wiki/Joseph_MurrayFamous Birthdays26 Nov 1898 - Karl Waldemar Ziegler, Germanchemist who won the Nobel Prize in Chemistry in 1963, with Giulio Natta, for work on polymers. The Nobel Committee recognized his "excellent work on organometallic compounds [which]...led to new polymerization reactions and ... paved the way for new and highly useful industrial processes". He is also known for his work involving free-radicals, many-membered rings, and organometallic compounds, as well as the development of Ziegler–Natta catalyst. One of many awards Ziegler received was the Werner von Siemens Ring in 1960 jointly with Otto Bayer and Walter Reppe, for expanding the scientific knowledge of and the technical development of new synthetic materials. He was born in Helsa near Kassel,German Empire - https://en.wikipedia.org/wiki/Karl_Ziegler26 Nov 1920 - István Sárközy, Hungarian composer, he was a founder-member of the Association of Hungarian Musicians and in 1954 he was appointed artistic adviser to the National Philharmonic Concert Bureau and the Hungarian Recording Company. In 1957 he was made general editor of Editio Musica and in 1959 he was appointed to teach theory at the Liszt Academy of Music, subsequently teaching composition there. Sárközy’s first work of lasting value was the Concerto grosso of 1943, though during that decade his attention was directed mainly to songs and folksong arrangements. In the early 1950s music for the stage dominated his creative activity, the crowning work of this period was the chamber cantata Júlia énekek (‘Julia Songs’, 1956), after which he composed little, until, in 1963 the Sinfonia concertante for clarinet and strings initiated a succession of major works. In 1975 Sárközy received the title Merited Artist of the Hungarian People’s Republic. After Confessioni (1979) for piano and orchestra he devoted himself exclusively to teaching. He was born in Pesterzsébet - https://www.oxfordmusiconline.com/grovemusic/view/10.1093/gmo/9781561592630.001.0001/omo-9781561592630-e-000002459126 Nov 1922 – Charles Monroe "Sparky" Schulz, American cartoonist and creator of the comic strip Peanuts (which featured the characters Charlie Brown and Snoopy, among others). He is widely regarded as one of the most influential cartoonists of all time, cited by cartoonists including Jim Davis, Bill Watterson, Matt Groening, Dav Pilkey, and Stephan Pastis. At its height, Peanuts was published daily in 2,600 papers in 75 countries, in 21 languages. Over nearly 50 years, Schulz drew 17,897 published Peanuts strips. The strips, plus merchandise and product endorsements, produced revenues of more than $1 billion per year, with Schulz earning an estimated $30 million to $40 million annually. He was born in Minneapolis, Minnesota - https://en.wikipedia.org/wiki/Charles_M._Schulz26 Nov 1988 - Hafþór Júlíus Björnsson, Icelandic professional strongman and actor. He is the first person to have won the Arnold Strongman Classic, Europe's Strongest Man and World's Strongest Man in the same calendar year. He played Gregor "The Mountain" Clegane in the HBO series Game of Thrones for five seasons. He also is a former professional basketball player. Hafþór won the Strongest Man in Iceland event in 2010, and won Iceland's Strongest Man in 2011. He won Europe's Strongest Man in 2014, a feat he repeated in 2015, 2017, 2018, and 2019. He won silver at the 2017 Arnold Strongman Classic, improving to gold in 2018 and 2019. He competed in his first World's Strongest Man in 2011, placing sixth. He won three bronze and three silver medals in his next six attempts before being crowned champion in 2018. He was born in Reykjavík - https://en.wikipedia.org/wiki/Haf%C3%BE%C3%B3r_J%C3%BAl%C3%ADus_Bj%C3%B6rnssonEvents of interest26 Nov 1865 - "Alice in Wonderland" by English author Charles Lutwidge Dodgson under the pseudonym Lewis Carroll was published in America. The was published as Alice's Adventures in Wonderland by "Lewis Carroll" with illustrations by John Tenniel. The first print run of 2,000 was held back because Tenniel objected to the print quality. The entire print run sold out quickly. Alice was a publishing sensation, beloved by children and adults alike. Among its first avid readers were Queen Victoria and the young Oscar Wilde. - https://en.wikipedia.org/wiki/Alice%27s_Adventures_in_Wonderland#Publication_history26 Nov 1977 – An unidentified hijacker named Vrillon, claiming to be the representative of the "Ashtar Galactic Command", takes over Britain's Southern Television for six minutes, starting at 5:12 pm. It was the first major broadcast interruption through the Hannington transmitter of the Independent Broadcasting Authority in the United Kingdom. The mystery has never been solved. - https://en.wikipedia.org/wiki/Southern_Television_broadcast_interruption26 Nov 1986 – Star Trek IV: The Voyage Home premiered. Since Star Trek had traditionally performed poorly internationally, the producers created a special trailer for foreign markets that de-emphasized the Star Trek part of the title, as well as retelling the events of The Wrath of Khan and The Search for Spock. Winter recalled that the marketing did not seem to make a difference. In its first week, The Voyage Home ended Crocodile Dundee's 8-week reign of the American box office. The Star Trek film made $39.6 million in its first five days of release, exceeding The Search for Spock's opening by $14 million. Ultimately, the film grossed a global total of $133,000,000 against its $21 million cost ($1 million under budget). Despite grossing $6,000,000 less than Star Trek: The Motion Picture,The Voyage Home was the most profitable of the series, grossing $133,000,000 against a $21,000,000 budget. - https://en.wikipedia.org/wiki/Star_Trek_IV:_The_Voyage_Home#ReleaseIntroArtist – Goblins from MarsSong Title – Super Mario - Overworld Theme (GFM Trap Remix)Song Link - https://www.youtube.com/watch?v=-GNMe6kF0j0&index=4&list=PLHmTsVREU3Ar1AJWkimkl6Pux3R5PB-QJFollow us onFacebook- Page - https://www.facebook.com/NerdsAmalgamated/- Group - https://www.facebook.com/groups/440485136816406/Twitter - https://twitter.com/NAmalgamatedSpotify - https://open.spotify.com/show/6Nux69rftdBeeEXwD8GXrSiTunes - https://itunes.apple.com/au/podcast/top-shelf-nerds/id1347661094RSS - http://www.thatsnotcanonproductions.com/topshelfnerdspodcast?format=rssInstagram - https://www.instagram.com/nerds_amalgamated/General EnquiriesEmail - Nerds.Amalgamated@gmail.com

Despite Australia's smoking rates continuing to drop, disadvantaged Australians remain over-represented among those getting ill through tobacco use. - Mặc dù tỷ lệ người hút thuốc ở Úc đang giảm dần, nhưng số người Úc thiệt thòi chịu nhiều khó khăn trong cuộc sống vẫn chiếm đa số trong nhóm những bệnh nhân bị mắc các căn bệnh liên quan đến việc sử dụng thuốc lá.

Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden

Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden

Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden

Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden

Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden

Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden

Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden

Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden

Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden

Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden

Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden

Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden

Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden

Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden

Spotlight on Disease Burden and Quality of Life in Atopic Dermatitis: Are We Missing the Big Picture?

Spotlight on Disease Burden and Quality of Life in Atopic Dermatitis: Are We Missing the Big Picture?

Spotlight on Disease Burden and Quality of Life in Atopic Dermatitis: Are We Missing the Big Picture?

Spotlight on Disease Burden and Quality of Life in Atopic Dermatitis: Are We Missing the Big Picture?

You've heard the statistic before -- 50% of the people living with MS will be diagnosed with depression. And research has shown us that some of the most troubling MS symptoms, including fatigue, cognition, and even physical disability, are all made worse by depression. Unfortunately, among people living with MS, depression is often overlooked, undiagnosed, and left to only get worse. So imagine an app that will tell you when you're heading toward depression before you even feel it. That's not science fiction -- it's science. My guest is Peta Slocombe the Senior V.P. of Corporate Health at mental health technology company, Medibio. We're talking about how Medibio's game-changing technology can improve the quality of life for people living with MS. We're also talking about iConquer MS -- a wide-ranging MS research community that's patient-focused, patient-managed, and patient-driven. Find out how you can be a part of iConquer MS and take an active role in unraveling the riddle of MS.  We'll tell you about about how and why your health insurance premium is going to increase, and how you can test-drive a smartphone app that will better personalize your MS treatment. We have a lot to talk about! Are you ready for RealTalk MS? ___________ Which Symptoms Matter Most to People Living with MS  1:43 You Can Participate in Patient-Centered MS Research with iConquer MS  3:29 Why New "Short Term" Insurance Rules Will Increase Your Health Insurance Premium  5:48 Test Drive an MS Smartphone App That Will Lead to Better Personalized MS Treatment  10:49 Interview with Peta Slocombe  12:07 ___________ LINKSIf your podcast app doesn’t show these links, you’ll find them in the show notes at www.RealTalkMS.com The Disease Burden of Multiple Sclerosis from the Individual and Population Perspective: Which Symptoms Matter Most? iConquer MS myMS App Medibio Share Your Feedback About RealTalk MS Give RealTalk MS a Rating & Review ___________ Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 47 Hosted By: Jon Strum Guest: Peta Slocombe Tags: MS, MultipleSclerosis, MSResearch, Medibio, Depression, RealTalkMS  

Interview with Eric L. Simpson, MD, MCR, author of Association of Inadequately Controlled Disease and Disease Severity With Patient-reported Disease Burden in Adults With Atopic Dermatitis

Dr John PETERSON MYERS, founder, CEO and Chief Scientist of Environmental Health Science

Editor's Audio Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the August 14, 2013 issue